Benzinga | Jan 20, 2022 08:15AM EST

F-star Announces Issuance Of US Patent Protecting FS118, A Bispecific Antibody Targeting PD-L1 And LAG-3

Provides U.S. Patent Protection to at least August 2038

Expands Patent Protection for FS118 Composition of Matter beyond Europe

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent protecting the composition of matter of FS118, F-star's tetravalent bispecific antibody which blocks PD-L1 and LAG-3 receptors. U.S. Patent No. 11,214,620 is entitled "Binding Molecules Binding PD-L1 and LAG-3" and is expected to provide F-star with exclusivity for FS118 out to at least August 2038.

Neil Brewis, Chief Scientific Officer of F-star Therapeutics, Inc., said: "This newly issued U.S. patent expands our already broad and robust patent portfolio and further supports the commercial potential of FS118. The growth of our IP portfolio surrounding our tetravalent bispecific antibody discovery platform, as well as our proprietary clinical-stage assets is a core strategic focus for F-star that we believe is creating significant value for our shareholders."

F-star currently has over 500 granted and pending patents covering its platform technology and product pipeline.